Drug Target Review

OCTOBER 26, 2023

1 Adeno-associated virus (AAV) vectors are the leading platform for in vivo gene delivery for the treatment of various human diseases. 9 In addition, host immune responses further add to the complexity of developing cell-specific AAV capsids for clinical applications. Nature Communications 6 , 6246 (2015). Grimm D, et al.

Engineering 104

Engineering Virus Therapies Immune Response 104

Drug Discovery World

APRIL 20, 2023

To date, it seems that the likely mechanism of post- Covid-19 cognitive impairment is neuroinflammation triggered by the peripheral / systemic inflammation caused by the virus. World Alzheimer Report 2015 The Global Impact of Dementia An Analysis of prevalence, Incidence, cost and trends.” KW Miskowiak et al., 82–92, Jun.

Drug Development 246

Drug Development Clinical Trials Drugs Virus 246

The Pharma Data

OCTOBER 21, 2020

headquartered in Woburn, MA, was founded in 2015 to develop the next generation of oncolytic immuno-gene therapies for the treatment of cancer. About Replimune Replimune Group, Inc.,

Immune Response 40

Immune Response Clinical Trials Production Therapies 40

Drug Discovery World

MAY 11, 2023

Another dangerous consequence can occur when the therapeutic or vaccine introduces proteins that can activate an uncontrolled immune response. In the case of therapeutics, the aim is usually to avoid patients’ immune responses. 2015): 1727-1737. ” Biotechnology and bioengineering 112.9 Collins, Ben C.,

Production 130

Production Vaccine Immune Response Therapies 130

The Pharma Data

JULY 21, 2021

Pfizer and Biovac have worked together since 2015 on the sterile formulation, fill, finish and distribution of the Prevenar 13 vaccine. Immunocompromised persons, including individuals receiving immunosuppressant therapy, may have a diminished immune response to the Pfizer-BioNTech COVID-19 Vaccine.

Vaccine 52

Vaccine Clinical Trials Licensing Licensing 52

The Pharma Data

APRIL 3, 2021

It is vital that we develop vaccines for everyone, everywhere, to help combat the spread of the virus with the goal to return to everyday life.”. Johnson & Johnson has worked with BARDA since 2015 on innovative solutions for influenza; chemical, biological, radiation and nuclear threats; and emerging infectious diseases such as Ebola.

Clinical Trials 52

Clinical Trials Vaccine Trials Immune Response 52

The Pharma Data

JULY 8, 2021

Specifically, tezepelumab targets and blocks thymic stromal lymphopoietin (TSLP), a key epithelial cytokine that sits at the top of multiple inflammatory cascades and initiates an overreactive immune response to allergic, eosinophilic and other types of airway inflammation associated with severe asthma.(24,25). 2015; 15: 57-65.

FDA 52

FDA Trials Therapies Treatment 52